Answers are grounded in this paper and cite their sources.
Chronic cutaneous graft-versus-host disease (GVHD) represents a common complication following allogeneic-hematologic stem cell transplant (allo-HSCT). Although GVHD has been well characterized in the context of allo-HSCT, autologous chimeric antigen receptor T-cell (CAR-T) therapy should, in theory, not exhibit self-reactivity because of thymic selection. However, it is important to note that patients may undergo CAR-T therapy after relapsing from allo-HSCT. Thus, the engineering of T cells procured from an allo-HSCT recipient with >95% donor chimerism is termed pseudoallogenic CAR-T therapy, given the likelihood of the engineered T cells originating from donor cell lines.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: